Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Amedisys Inc (NASDAQ: AMED) was $100.96 for the day%, Up $0.02% from the previous closing price of $100.94. In other words, the price has increased by $0.02 from its previous closing price. On the day, 0.88 million shares were traded. AMED stock price reached its highest trading level at $101.01 during the session, while it also had its lowest trading level at $100.85.
Ratios:
Our analysis of AMED’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.16. For the most recent quarter (mrq), Quick Ratio is recorded 1.36 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.31.
Truist Downgraded its Buy to Hold on June 07, 2023, while the target price for the stock was maintained at $97.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 08 ’25 when Guidroz Allyson sold 374 shares for $96.00 per share. The transaction valued at 35,904 led to the insider holds 8,114 shares of the business.
Guidroz Allyson bought 374 shares of AMED for $35,853 on May 08 ’25. On Mar 04 ’25, another insider, Guidroz Allyson, who serves as the Chief Accounting Officer of the company, sold 2,041 shares for $92.03 each. As a result, the insider received 187,833 and left with 8,761 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMED now has a Market Capitalization of 3320241152 and an Enterprise Value of 3475817472. As of this moment, Amedisys’s Price-to-Earnings (P/E) ratio for their current fiscal year is 39.31, and their Forward P/E ratio for the next fiscal year is 19.54. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.38 while its Price-to-Book (P/B) ratio in mrq is 2.69. Its current Enterprise Value per Revenue stands at 1.447 whereas that against EBITDA is 13.735.
Stock Price History:
The Beta on a monthly basis for AMED is 0.90, which has changed by 0.029573679 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, AMED has reached a high of $100.99, while it has fallen to a 52-week low of $82.15. The 50-Day Moving Average of the stock is 3.69%, while the 200-Day Moving Average is calculated to be 8.15%.
Shares Statistics:
AMED traded an average of 478.47K shares per day over the past three months and 1058610 shares per day over the past ten days. A total of 32.88M shares are outstanding, with a floating share count of 32.12M. Insiders hold about 2.33% of the company’s shares, while institutions hold 91.13% stake in the company. Shares short for AMED as of 1753920000 were 3198679 with a Short Ratio of 4.68, compared to 1751241600 on 2157695. Therefore, it implies a Short% of Shares Outstanding of 3198679 and a Short% of Float of 9.9.
Earnings Estimates
Investors are keenly observing as 10.0 analysts analyze and rate the current performance of Amedisys Inc (AMED) in the stock market.The consensus estimate for the next quarter is $1.16, with high estimates of $1.25 and low estimates of $1.01.
Analysts are recommending an EPS of between $5.31 and $4.87 for the fiscal current year, implying an average EPS of $5.09. EPS for the following year is $5.12, with 11.0 analysts recommending between $5.63 and $4.75.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $623.2M to a low estimate of $611.3M. As of the current estimate, Amedisys Inc’s year-ago sales were $587.67MFor the next quarter, 11 analysts are estimating revenue of $628.58M. There is a high estimate of $636.3M for the next quarter, whereas the lowest estimate is $620.42M.
A total of 10 analysts have provided revenue estimates for AMED’s current fiscal year. The highest revenue estimate was $2.48B, while the lowest revenue estimate was $2.45B, resulting in an average revenue estimate of $2.47B. In the same quarter a year ago, actual revenue was $2.35BBased on 11 analysts’ estimates, the company’s revenue will be $2.58B in the next fiscal year. The high estimate is $2.66B and the low estimate is $2.52B.
